Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Astellas_Pharma
|
| gptkbp:acquisitionYear |
2023
|
| gptkbp:CEO |
gptkb:Glenn_P._Sblendorio
|
| gptkbp:clinicalTrialPhase |
gptkb:GATHER1
gptkb:GATHER2 |
| gptkbp:focusesOn |
ophthalmology
retinal diseases |
| gptkbp:formerName |
gptkb:Ophthotech_Corporation
|
| gptkbp:foundedYear |
2007
|
| gptkbp:headquartersLocation |
gptkb:Parsippany,_New_Jersey,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Iveric Bio
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:Zimura
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:specializesIn |
complement C5 inhibition
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:ISEE
|
| gptkbp:website |
https://www.ivericbio.com/
|
| gptkbp:bfsParent |
gptkb:Astellas_Pharma
|
| gptkbp:bfsLayer |
5
|